盐酸法舒地尔联合尼莫地平治疗脑外伤性蛛网膜下腔出血患者的临床研究

发布时间：2019-05-11 16:26

【摘要】：目的观察盐酸法舒地尔联合尼莫地平治疗脑外伤性蛛网膜下腔出血的临床疗效及安全性。方法将100例脑外伤性蛛网膜下腔出血患者随机分为对照组50例与试验组50例。对照组予以尼莫地平注射液持续静脉泵入,前2 h速度为0.5 mg·h~(-1),后将速度调整为1 mg·h~(-1)。试验组在对照组治疗的基础上,给予静脉滴注盐酸法舒地尔注射液30 mg,qd。2组患者均连续治疗2周。比较2组患者的临床疗效、脑血流速度、神经功能评分、肝肾功能及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为92.00%(46/50例)和82.00%(41/50例),差异无统计学意义(P0.05)。治疗后,试验组和对照组的欧洲卒中评分分别为(86.72±11.16),(75.28±10.59)分;日常生活能力评分分别为(73.27±10.05),(51.21±7.29)分,差异有统计学意义(P0.05)。治疗后,试验组与对照组的大脑中动脉血流速度分别为(79.68±11.32),(82.27±12.19)cm·s~(-1);血清谷丙转氨酶分别为(22.78±3.06),(23.01±3.21)U·L~(-1);谷草转氨酶分别为(23.76±3.18),(24.72±3.26)U·L~(-1);肌酸酐分别为(57.15±8.26),(56.29±8.03)μmol·L~(-1);尿素氮分别为(4.33±0.66),(4.25±0.62)mmol·L~(-1),2组比较差异均无统计学意义(P0.05)。2组患者的药物不良反应均为头疼、发热、面红,试验组和对照组的药物不良反应发生率分别为12.00%和22.00%,差异有统计学意义(P0.05)。结论盐酸法舒地尔联合尼莫地平治疗脑外伤性蛛网膜下腔出血的临床疗效确切,且安全性较高。
[Abstract]:Objective to observe the clinical efficacy and safety of fasudil hydrochloride combined with nimodipine in the treatment of traumatic subarachnoid hemorrhage. Methods 100 patients with traumatic subarachnoid hemorrhage were randomly divided into control group (n = 50) and trial group (n = 50). In the control group, nimodipine injection was continuously injected intravenously, the velocity was 0.5 mg 路h ~ (- 1) at the first 2 h, and then adjusted to 1 mg 路h ~ (- 1). On the basis of the treatment in the control group, the patients in the experimental group were treated by intravenous drip of fasudil hydrochloride for 30 mg,qd.2 for 2 weeks. The clinical efficacy, cerebral blood flow velocity, neurological function score, liver and kidney function and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the experimental group and the control group were 92.00% (46 鈮，

本文编号：2474656